AR037111A1 - SOLID FORMULATION TO USE AS A MEDICATION BASED ON A PIPERAZINUREA DERIVATIVE PROCEDURE FOR PREPARATION AND USE - Google Patents

SOLID FORMULATION TO USE AS A MEDICATION BASED ON A PIPERAZINUREA DERIVATIVE PROCEDURE FOR PREPARATION AND USE

Info

Publication number
AR037111A1
AR037111A1 ARP020103929A ARP020103929A AR037111A1 AR 037111 A1 AR037111 A1 AR 037111A1 AR P020103929 A ARP020103929 A AR P020103929A AR P020103929 A ARP020103929 A AR P020103929A AR 037111 A1 AR037111 A1 AR 037111A1
Authority
AR
Argentina
Prior art keywords
solid formulation
piperazinurea
preparation
medication based
derivative procedure
Prior art date
Application number
ARP020103929A
Other languages
Spanish (es)
Inventor
Tack Johannes
Heiko Kranz
Christoph Voelkel
Ralph Lipp
Herbert Wiesinger
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR037111A1 publication Critical patent/AR037111A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Formulación sólido para utilizar como medicamento que contiene (2R)-1-((4-cloro-2-(ureido)fenoxi)metil)carbonil-2-metil-4-(4-fluoro-bencil)-piperazina o una de sus sales caracterizada porque contiene adicionalmente una matriz polimérica, un ácido orgánico, un lubricante y uno o varios excipientes y porque el 90% de los tamanos de partículas de las mezclas en polvo se ubican en el rango de 0,1 a 750 micrones.Claim 1: Solid formulation for use as a medicament containing (2R) -1 - ((4-chloro-2- (ureido) phenoxy) methyl) carbonyl-2-methyl-4- (4-fluoro-benzyl) -piperazine or one of its salts characterized in that it additionally contains a polymer matrix, an organic acid, a lubricant and one or several excipients and because 90% of the particle sizes of the powder mixtures are in the range of 0.1 to 750 microns .

ARP020103929A 2001-10-18 2002-10-18 SOLID FORMULATION TO USE AS A MEDICATION BASED ON A PIPERAZINUREA DERIVATIVE PROCEDURE FOR PREPARATION AND USE AR037111A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10152351A DE10152351B4 (en) 2001-10-18 2001-10-18 Solid drug formulation for a piperazine urea derivative

Publications (1)

Publication Number Publication Date
AR037111A1 true AR037111A1 (en) 2004-10-20

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103929A AR037111A1 (en) 2001-10-18 2002-10-18 SOLID FORMULATION TO USE AS A MEDICATION BASED ON A PIPERAZINUREA DERIVATIVE PROCEDURE FOR PREPARATION AND USE

Country Status (23)

Country Link
EP (1) EP1435917A1 (en)
JP (1) JP2005506365A (en)
KR (1) KR20040047920A (en)
CN (1) CN1571660A (en)
AR (1) AR037111A1 (en)
AU (1) AU2002333896B2 (en)
BR (1) BR0213340A (en)
CA (1) CA2463951A1 (en)
CO (1) CO5580740A2 (en)
DE (1) DE10152351B4 (en)
EC (1) ECSP045108A (en)
HR (1) HRP20040435A2 (en)
IL (1) IL161166A0 (en)
MX (1) MXPA04003522A (en)
NO (1) NO20042022L (en)
NZ (1) NZ532287A (en)
PE (1) PE20030472A1 (en)
PL (1) PL367987A1 (en)
RS (1) RS32204A (en)
RU (1) RU2311172C2 (en)
UY (1) UY27500A1 (en)
WO (1) WO2003035037A1 (en)
ZA (1) ZA200403781B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60222667T2 (en) 2001-06-27 2008-07-17 Smithkline Beecham Corp. FLUORPYRROLIDINES AS DIPEPTIDYLPEPTIDASE INHIBITORS
EP1749519A1 (en) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Dosage form with pH-independent sustained release for active substances with pH-dependent solubility
WO2007121537A1 (en) * 2006-04-26 2007-11-01 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
KR101654582B1 (en) 2016-05-12 2016-09-06 그린로드(주) Conical Shaped Buoyant Polymer Filter and Apparatus for Manufacturing the same and Method for Manufacturing the same and Water Treatment Filter including the same
RU2729223C1 (en) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Dosage form for amplification of nucleic acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
UA57824C2 (en) * 1998-02-05 2003-07-15 Пфайзер Продактс Інк. NEW Dihydroxyhexanoic acid derivatives
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability

Also Published As

Publication number Publication date
AU2002333896A2 (en) 2003-05-06
HRP20040435A2 (en) 2005-06-30
ECSP045108A (en) 2004-06-28
DE10152351B4 (en) 2005-09-22
RS32204A (en) 2006-10-27
EP1435917A1 (en) 2004-07-14
NO20042022L (en) 2004-05-14
RU2311172C2 (en) 2007-11-27
CO5580740A2 (en) 2005-11-30
UY27500A1 (en) 2003-06-30
PE20030472A1 (en) 2003-06-16
IL161166A0 (en) 2004-08-31
AU2002333896B2 (en) 2007-07-26
CN1571660A (en) 2005-01-26
WO2003035037A1 (en) 2003-05-01
JP2005506365A (en) 2005-03-03
DE10152351A1 (en) 2003-05-08
ZA200403781B (en) 2004-11-29
NZ532287A (en) 2007-04-27
BR0213340A (en) 2004-10-05
MXPA04003522A (en) 2004-07-23
RU2004115328A (en) 2005-06-10
KR20040047920A (en) 2004-06-05
PL367987A1 (en) 2005-03-21
CA2463951A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
AR084101A2 (en) COMPRESSED HIGH DRUG LOAD AND PROCESS FOR PREPARATION
UY28510A1 (en) CHEMICAL COMPOUNDS
HN2002000275A (en) DERIVATIVES OF 1.8 NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
UY28342A1 (en) NEW COMPOUNDS
PA8551001A1 (en) NEW COMPOUNDS
BRPI0615292A8 (en) compositions and methods for preparing poorly soluble water drugs with increased stability
AR048963A1 (en) POLOXAMERO HYDROGEL INTERFER FORMULATIONS
ECSP055747A (en) CGRP ANTAGONISTS ELECTED, PROCEDURE FOR PREPARATION, AS WELL AS ITS EMPLOYMENT AS MEDICATIONS
SV2008001369A (en) BENZIMIDAZOLES
ECSP034895A (en) PHARMACEUTICAL COMPOSITIONS OF AMORFO DRUG ADSORBATES
NO20080220L (en) Formulations with high drug loading and dosage forms
SV2008002527A (en) PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENS AND / OR STROGENS AND 5-METHYL- (6S) -TETRAHYDROPHOLATE REF. P-SV-80.273 / UG
ECSP088296A (en) THERAPEUTIC COMPOUNDS
AR034813A1 (en) PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
AR037111A1 (en) SOLID FORMULATION TO USE AS A MEDICATION BASED ON A PIPERAZINUREA DERIVATIVE PROCEDURE FOR PREPARATION AND USE
UY28357A1 (en) DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATION OF THE SAME AND ITS USES
GT200500120A (en) ESTRIOL AND ESTETROL PRODUCTS
CL2004001843A1 (en) COMBINATION OF (A) AT LEAST A 2,5-DIHYDROBENCENOSULPHONIC DERIVATIVE, AS CALCIUM DOBEYLATE, ETHAMSYLATE AND PERSILATE, AND (B) AT LEAST A MODULATOR OF POTASSIUM CHANNELS, PHARMACEUTICAL COMPOSITION CONTAINING AND USE AS A MEDICATION IN PROFILA
UY27753A1 (en) PHARMACEUTICAL FORMULATION THAT MELATONINE INCLUDES.
UY29561A1 (en) DERIVATIVES OF QUINAZOLINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS
UY28685A1 (en) HETEROCICLES WITH NITROGEN CONTENT AFFECTING THE SYNTHETIC GLUTAMATERIC TRANSMISSION
ES2052484T1 (en) N- (5-TIOXO-L-PROLIL) -L-CYSTEINE, ITS DERIVATIVES, PROCEDURES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
AR013261A1 (en) PHARMACEUTICAL FORMULATIONS FOR CAMPTOTECINE ANALOGS IN A GELATIN CAPSULE
ES2129448T3 (en) USE OF 2- (2-NITRO-4-TRIFLUOROMETILBENZOIL) -1,3-CYCLLOHEXANODIONA IN THE TREATMENT OF THYROSINEMIA AND PHARMACEUTICAL COMPOSITIONS.
BRPI0520821A2 (en) fenofibrate pharmaceutical formulations with improved bioavailability

Legal Events

Date Code Title Description
FB Suspension of granting procedure